Immunologic profiles of effector cells and peripheral blood stem cells mobilized with different hematopoietic growth factors

Stem Cells

Volumn 18, Issue 6, 2000, Pages 390-398

  Gazitt, Yair ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

CD34+ cells; CXCR4; L Selectin; Mobilization; VLA 4

Indexed keywords

BETA1 INTEGRIN; CD34 ANTIGEN; CD45 ANTIGEN; CD56 ANTIGEN; CHEMOKINE RECEPTOR CXCR4; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; L SELECTIN;

AUTOTRANSPLANTATION; CELL MOTILITY; DENDRITIC CELL; EFFECTOR CELL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; NATURAL KILLER CELL; REVIEW; T LYMPHOCYTE;

EID: 0033767407     PISSN: 10665099     EISSN: None     Source Type: Journal    
DOI: 10.1634/stemcells.18-6-390     Document Type: Review

References (89)

1. Characterization of chemotherapy mobilized peripheral blood progenitor cells for use in autologous stem cell transplantation
2. Factors affecting blood stem cell collection following high dose cyclophosphamide mobilization in lymphoma, myeloma and solid tumors
3. Transplantation potential of peripheral blood stem cells induced by G-CSF
4. Optimization of stem cell mobilization
5. Transplantation of hematopoietic cells released into the peripheral blood for non-Hodgkin's lymphoma
6. Use of granulocyte colony-stimulating factor (G-CSF) for mobilizing peripheral blood stem cells: Risk of mobilizing clonal myeloma cells in patients with bone marrow infiltration
7. Autologous transplantation with peripheral blood mononuclear cells after administration of G-CSF
8. Granulocyte colony stimulating factor mobilized peripheral blood progenitor cells accelerate granulocyte and platelet recovery after high dose chemotherapy
9. Differential mobilization of myeloma cells and normal hematopoietic stem cells in multiple myeloma after treatment with cyclophosphamide and GM-CSF
10. + cell yields
11. Successful PBSC mobilization with high dose G-CSF for patients failing a first round of mobilization
12. Progenitor-cell mobilization after low-dose cyclophosphamide and granulocyte colony-stimulating factor: An analysis of progenitor-cell quantity and quality and factors predicting for these parameters in 101 pretreated patients with malignant lymphoma
13. Comparative effect of GM-CSF and G-CSF on priming of peripheral blood progenitor cells for use with autologous bone marrow after high dose chemotherapy
14. Granulocyte-macrophage colony-stimulating factor to harvest circulating haemopoietic stem cells for autotransplantation
15. + cells mobilized by G-CSF
16. Collection, engraftment kinetics and tumor contamination of highly purified hematopoietic progenitor cells to support high dose therapy in multiple myeloma
17. Harvesting and enrichment of HPC mobilized into the peripheral blood of normal donors by GM-CSF or G-CSF: Potential role in allogeneic transplantation
18. Composition of peripheral blood progenitor cell components collected from healthy donors
19. Phase I/II study of combined G-CSF and GM-CSF administration for the mobilization of hematopoietic progenitor cells
20. Randomized comparison of G-CSF + GM-CSF vs G-CSF alone for mobilization of peripheral blood stem cells: Effects on hematopoietic recovery after high-dose chemotherapy
21. Recombinant human granulocyte and granulocyte-macrophage colony-stimulating factor (G-CSF and GM-CSF) administered following cytotoxic chemotherapy have a similar ability to mobilize peripheral blood stem cells
22. Peripheral blood stem cell mobilization with cyclophosphamide in combination with G-CSF, GM-CSF, or sequential GM-CSF followed by G-CSF in non Hodgkin's lymphoma patients: A randomized prospective study
23. IL-2 expansion of T and NK cells from growth factor mobilized peripheral blood stem cells product: Monocyte inhibition
24. Comparison of monocyte dependent T cell inhibitory activity in GM-CSF versus G-CSF mobilized PSC products
25. Granulocyte colony stimulating factor transiently suppresses mitogen stimulated T-cells
26. Inhibitory effect of granulocyte-macrophage colony-stimulating factor therapy on the generation of natural killer cells
27. Suppression of natural killer cell activity by granulocytes in patients with aplastic anemia: Role of granulocyte colony stimulating factor
28. Alloantigen presenting capacity, T cell alloreactivity and NK function of G-CSF-mobilized peripheral blood cells
29. + cell selection
30. Natural killer cells are functionally abnormal and NK cell progenitors are diminished in granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cell collections
31. Natural killer cell numbers and activity in mobilized peripheral blood stem cell grafts: Conditions for in vitro expansion
32. Suppressive effect of granulocyte macrophage stimulating factor on the generation of natural killer cells in vitro
33. Functional and phenotypic characterization of human peripheral blood stem cells: A comparative analysis of cells from consecutive collections
34. Immunological phenotype and function in human bone marrow stem cells and umbilical cord blood
35. Recombinant human GM-CSF enhances T cell-mediated cytotoxicity after ABMT for hematological malignancies
36. A randomized study of peripheral blood stem cell mobilization with cyclophosphamide in combination with G-CSF, GM-CSF and sequential GM-CSF followed by G-CSF in non-Hodgkin's lymphoma patients: Co-mobilization of dendritic cells and NK-cells
37. Stem cell factor enhances IL-2 mediated expansion of murine natural killer cells in vivo
38. Immunological properties of mononuclear cells from blood stem cell harvests following mobilization with erythropoietin + G-CSF in cancer patients
39. Dendritic cells: Unique leukocyte population which control primary immune response
40. Human CD14 leukocytes acquire the phenotype and function of antigen presenting dendritic cells when cultured in GM-CSF and IL-4
41. GM-CSF and TNF-alpha cooperate in the generation of dendritic Langerhans cells
42. + hematopoietic progenitor cells of the bone marrow and peripheral blood
43. + cells
44. + murine hematopoietic progenitor cells
45. Stem cell factor augments tumor necrosis factor granulocyte macrophage colony stimulating factor mediated dendritic cell hematopoiesis
46. + cells isolated from G-CSF mobilized blood to differentiate in vitro into potent antigen presenting cells
47. The generation of human dendritic and NK cells from hemopoietic progenitors induced by interleukin-15
48. Flt3 ligand in cooperation with transforming growth factor beta-1 potentiates in vitro development of Langerhans-type dendritic cells and allows single cell dendritic cell cluster formation under serum free conditions
49. + cells
50. CD1 molecule expression on human monocytes induced by granulocyte-macrophage colony-stimulating factor
51. Involvement of CD80 in the generation of cytotoxic T cells
52. Dendritic cell based vaccine: A promising approach for cancer immunotherapy
53. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells
54. Phase I clinical trial: T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostate specific membrane antigen
55. + cell-depleted mobilized peripheral blood can serve as a source of potent dendritic cells
56. Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma - A feasibility study
57. Development of dendritic cells and their use in tumor therapy
58. Approaches to dendritic cell-based immunotherapy after peripheral blood stem cell transplantation
59. + hematopoietic progenitor cells: Induction of autologous cytotoxic T lymphocytes against leukemic cells in acute myelogenous leukemia patients
60. A comparative study of the generation of dendritic cells from mobilized peripheral blood progenitor cells of patients undergoing high-dose chemotherapy
61. Selective in vivo mobilization with granulocyte macrophage colony-stimulating factor (GM-CSF)/granulocyte-CSF as compared to G-CSF alone of dendritic cell progenitors from peripheral blood progenitor cells in patients with advanced breast cancer undergoing autologous transplantation
62. + cells in cancer patients
63. + cells and rapid hematopoietic recovery after peripheral blood stem cell transplantation
64. - cells in early and late trilineage hematopoietic engraftment after autologous blood cell transplantation
65. Successful reconstitution of human hematopoiesis in the SCID-hu mouse genetically modified highly enriched progenitors isolated from fetal liver
66. Isolation of a candidate human hematopoietic stem cell population
67. Expression of Thy-1 on human hematopoietic progenitor cells
68. Primitive human hematopoietic cells are enriched in cord blood compared with adult bone marrow or mobilized peripheral blood as measured by quantitative in vivo SCID repopulating cell assay
69. Emerging applications of recombinant human granulocyte-macrophage colony stimulating factor
70. - cells in lymphohematopoiesis
71. Technical aspects and clinical impact of hematopoietic progenitor subset quantification
72. + cells during mobilization with G-CSF
73. + cells in grafts and time to myeloid and platelet recovery after autologous stem cell transplantation
74. + cells in adhesion molecule expression
75. + progenitor cells from bone marrow and peripheral blood during G-CSF-enhanced recovery
76. + cells predict a rapid platelet recovery after peripheral blood stem cell transplantation
77. + cells from bone marrow and G-CSF mobilized peripheral blood
78. Mobilization of hematopoietic primitive and committed progenitor cells into blood in mice by anti-vascular adhesion molecule-1 antibody alone or in combination with granulocyte colony stimulating factor
79. Role of adhesion molecules in the homing and mobilization of murine hematopoietic stem and progenitor cells
80. + cells
81. Cytokines increase human hematopoietic cell adhesiveness by activation of very late antigen (VLA)-4 and VLA-5
82. + hematopoietic stem cells
83. + hematopietic progenitors and leukemic cells and mediates transendothelial migration induced by stromal cell-derived factor-1
84. SLC/exodus2/6Ckine/TCA4 induces chemotaxis of hematopoietic progenitor cells: Differential activity of ligands of CCR7, CXCR3, or CXCR4 in chemotaxis versus suppression of progenitor proliferation
85. + cells express CXCR4 and its ligand stromal cell-derived factor-1. Implications for infection by T-cell tropic human immunodeficiency virus
86. Expression of CXCR4, the receptor for stromal cell-derived factor-1 on fetal and adult human lympho-hematopoietic progenitors
87. Dependence of human stem cell engraftment and repopulation of NOD/SCID mice on CXCR4
88. + cell proliferation in synergy with cytokines: Possible role in progenitor survival
89. + cells in mobilized peripheral blood of non-Hodgkin's lymphoma patients